Want to see MREO full AI Analyst Report?
MREO Stock Chart & Stats
$0.27
>-$0.01(-1.10%)
At close: 4:00 PM EDT
$0.27
>-$0.01(-1.10%)
Day’s Range― - ―
52-Week Range$0.20 - $2.37
Previous CloseN/A
Volume389.50K
Average Volume (3M)1.57M
Market Cap
$44.96M
Enterprise Value$21.97M
Total Cash (Recent Filing)$30.12M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 17, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding159,690,980
10 Day Avg. Volume770,663
30 Day Avg. Volume1,570,847
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-24.50
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$3.00Price Target Upside1011.11% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal reported debt reduces solvency pressure and limits interest-related demands on future cash flows. This relatively conservative leverage profile gives Mereo more financial flexibility than a highly indebted biotech, although ongoing losses still weaken its overall financial position.
Capital-light Partnership StrategyThe Sentynl agreement creates potential non-dilutive economics while transferring U.S. commercial and global manufacturing rights to a partner. If the option is exercised and development succeeds, milestone and royalty income could support Mereo’s pipeline without requiring it to build a broad commercial infrastructure.
Rare-disease Pipeline FocusConcentrating on oncology and rare diseases can support differentiated development opportunities where unmet needs are substantial and patient populations may be defined. This focus aligns with Mereo’s stated goal of creating value through novel therapies and partnering or commercializing successful candidates.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the business is not currently self-funding its development activities. Continued burn raises the need for financing, partnerships, or other capital sources, potentially limiting strategic flexibility and increasing execution risk over the next several quarters.
Near-zero Revenue And Continuing LossesNear-zero current revenue provides little support for the company’s cost base, while sizable net losses indicate that clinical development has not yet translated into recurring operating income. Without successful advancement or partnering of candidates, earnings durability remains weak and dependent on external funding.
Nasdaq Compliance RiskThe additional Nasdaq compliance period extends a material listing risk rather than resolving it. Failure to regain the minimum bid requirement could lead to delisting, reducing market visibility and potentially complicating access to public-market financing that is important for a cash-burning clinical-stage company.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $0.20 and its highest was $2.37 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $44.96M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 17, 2026 which is in 23 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 11, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.02.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,690,980 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went up 12.132%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (1011.11% Upside)
$3.00 (1011.11% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-85.95%
12-Months-Change
Fundamentals
Return on Equity
-74.76%
Trailing 12-Months
Asset Growth
-44.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MREO Stock 12 Month Forecast
Average Price Target
$3.00
▲(1011.11% Upside)
Technical Analysis
Ownership Overview
0.81%
Insiders
0.09% Mutual Funds
0.07% Other Institutional Investors
99.02% Public Companies and
Individual Investors